checkAd

     279  0 Kommentare JonesTrading's George Zavoico Interviewed by The Life Sciences Report

    SAN FRANCISCO, CA--(Marketwired - April 14, 2016) - While the vagaries of the 2016 political season create uncertainty in the biotech and pharmaceutical sectors, companies are moving ahead with innovative cell therapies, gene therapies and new, safer ways to deliver addictive drugs, and investors find themselves in a position to play the development ideas with varying degrees of risk. In this interview with The Life Sciences Report, George Zavoico of Jones Trading Institutional Services explores how the presidential race could affect the biotech industry, and explains the growth prospects of three biotech names that could strike gold.

    Included in this interview is: DURECT Corp.  (NASDAQ: DRRX).

    [Editor's Note: This is part two of a two-part series with Dr. George Zavoico.]

    The Life Sciences Report: Right now, the U.S. government cannot negotiate the price of drugs with pharmas and biopharmas. If policy changes under a new administration, what effect would that have on drug developers?

    George Zavoico You really don't know what a candidate will do until he or she is elected. Governing is different from campaigning. Once elected, I'm hopeful the new president and Congress, no matter which party is in control, will remember that it's in no one's best interest to drive drug companies out of business. The U.S. is leading the world in biotech and pharma industries, and not much should be done to disrupt that fact.

    Having said that, I think whoever is elected will make an effort to change policy, if only to satisfy their base and follow up on campaign promises. So I suspect there will be attempts to…

    Continue reading this interview: Drug Pricing, Presidential Politics, and Three Biotechs with Promise

    About Streetwise Reports - The Life Sciences Report

    Investors rely on The Life Sciences Report to share investment ideas for the biotech, pharmaceutical, medical device, and diagnostics industries. Our exclusive interviews with leading industry experts and analysts provide a clear picture of the causes of macro-economic shifts and the strategies that help you capitalize on developing trends.

    DISCLOSURE:

    DURECT Corp. is a sponsor of Streetwise Reports. George Zavoico had final approval of the content and is wholly responsible for the validity of the statements. Opinions expressed are the opinions of Mr. Zavoico and not of Streetwise Reports or its officers. The interview does not constitute investment advice. Each reader is encouraged to consult with his or her individual financial professional and any action a reader takes as a result of information presented here is his or her own responsibility.

    Please see Streetwise Reports' terms of use and full legal disclaimer.

    Contact Information
    Jim Patrick
    jpatrick@streetwisereports.com





    Verfasst von Marketwired
    JonesTrading's George Zavoico Interviewed by The Life Sciences Report SAN FRANCISCO, CA--(Marketwired - April 14, 2016) - While the vagaries of the 2016 political season create uncertainty in the biotech and pharmaceutical sectors, companies are moving ahead with innovative cell therapies, gene therapies and new, …